lab.parkview.comParkview Health Laboratory: Test Directory

Parkview Laboratory: Test Directory Home Test Directory About Us Mission & Vision Statements Medical Directors and Technical Consultants Administrators Certification and Accreditation Information Laboratory Locations Patient Information Where can I get my blood drawn? Pay your Bill, Get a Price Estimate, Is Parkview In Network My Chart - Get Access / Get Lab Results Patient Collection Instructional Sheets Lab Links Parkview Health External Lab Resource PHL Clients ICD-9 to ICD-10 MEDICARE NUMBER AND CARD CHANGES PHL Test Requisitions Inappropriate Duplicate Testing Flow Cytometry Ordering Guidelines Certification and Accreditation Information Cytology Collection Information Specimen Collection and Handling Requirements Histology Collection Information Microbiology Specimen Collection, Rejection and Safety Information Specimen Types, Descriptions, and Definitions Billing (Insurance/Account/Patient/Medicare) Definitions and Information Supply Needs Customer Service LabView - Newsletters for Physicians and Clients How to use this Online Directory Physicians Quick Reference for Medicare Preventive Services View Medical Necessity Guide View Stat Eligible Testing Report Parkview Labs News: March 2020 Effective March 24, 2020, serum amylase will be removed from the lab trauma (EPIC code LAB2650) and sepsis (EPIC code LAB2428) panels. This is being done at the recommendation of the Parkview Health Test Utilization Committee in following the ASCP Choosing Wisely Recommendations. This change is coordinated with the removal of amylase from many EPIC order sets. Please refer questions about these panel changes to Dr. Qi Wang, Chemistry Technical Director, at 266-1641 or Ann Vick, Lab Chemistry Specialist, at 266-1587. Additional information regarding Choosing Wisely Recommendations may be found at https://www.ascp.org/content/get-involved/choosing-wisely . February 2020 Intuitively Named Pathology Reports Beginning on February 19th, Pathology Reports will be named intuitively & can be viewed in the Path/Cyto Filter. The Lab Results Tree will also be updated to allow Pathology Reports to be located more easily & intuitively. DAT w/ Reflex Elution Beginning February 12, 2020, the test set DAT with Reflex Elution (EPIC Test Code: LAB3172) will be performed by Parkview Health Laboratories at Parkview Regional Medical Center. This cascade of testing will aid in the diagnosis of autoimmune hemolytic anemia. The specimen requirement for this test set is one pink tube. Please refer questions about this test set to Blood Bank Medical Director Dr. Craig McBride at 266-1637 or Blood Bank Specialist Annie Ilnicki at 266-6085. Methodology Changes for the Strep A Strep A by isothermal nucleic acid amplification (NAA) will be replacing the Rapid Strep A test on February 19, 2020. The new Strep A by NAA is a rapid, instrument-based, molecular diagnostic test utilizing isothermal DNA amplification technology for the qualitative detection of Streptococcus pyogenes, collected from throat swab specimens. It is intended to aid in the rapid diagnosis of Group A Streptococcus bacterial infections. This assay meets the FDA requirements for no culture confirmation for negative results. There is no need to perform a culture on negative results for patients <18 years old, as the result is a true negative. This new test will be performed at all the hospital labs, as well as the Ohio draw sites. Please review included documentation*, and contact Dr. Craig McBride at 266-1637 or Landers Barber at 266-1593 with any further questions. January 2020 The Myelin Basic Proteins, from the MS Panel are being delayed due to reagent issues. The specimens sent will be held to be ran after reagent issue resolved. All other tests in the MS Panel are being resulted. Please contact the Carey Jacquay for any further questions at 266-1505. October 9, 2019 H-Pylori Stool Effective November 4, 2019, Helicobacter pylori Stool Antigen (EPIC Test Code LAB2596) will be performed by Parkview Health Laboratories at Parkview Regional Medical Center Helicobacter pylori IgG (EPIC Test Code IMO28) testing will be discontinued. These changes are being made to better comply with current testing guidelines from the American College of Gastroenterology for the diagnosis and monitoring of Helicobacter pylori infection. Please refer questions about these test changes to Dr. Qi Wang, Chemistry Technical Director, at 266-1641 or Ann Vick, Laboratory Chemistry Specialist, at 266-1587. Kappa/Lambda Effective October 30, 2019, serum free kappa and lambda light chain with ratio (EPIC Test Code LAB2545) testing will be performed by Parkview Health Laboratories at Parkview Regional Medical Center. Specimen requirements and reference ranges remain the same as those for the testing currently sent to Quest Diagnostics. Testing will be performed using the Freelite assay on the Roche Cobas c502. Please refer any questions about this test change to Dr. Qi Wang, Chemistry Technical Director, at 266-1641 or Ann Vick, Laboratory Chemistry Specialist, at 266-1587. August 22, 2019 Beginning September 18, 2019, PSA, Free and Total (EPIC Test Code: LAB171) testing will be performed by Parkview Health Laboratories at PRMC. Specimen requirements remain the same as those for the testing currently sent to Quest Diagnostics. Testing will be performed using electrochemiluminesence immunoassay (ECLIA) technology on the Roche Cobas e801. The following result interpretation is provided. The diagnostic usefulness of % Free PSA has not been established in patients with total PSA below 2.6 ng/mL. In men with total PSA values above 10.0 ng/mL, prostate cancer risk is determined by total PSA alone. In patients with total PSA concentrations of 4-10 ng/ml the probability of finding prostate cancer on needle biopsy by age in years is: %FREE PSA PROBABILITY IN CANCER BY AGE IN YRS 50-59 YRS 60-69 YRS >=70 YRS <=10 49% 58% 65% 11-18 27% 34% 41% 19-25 18% 24% 30% >25 9% 12% 16% Please refer any questions about this test change to Dr. Qi Wang, Chemistry Technical Director, at 266-1641 or Ann Vick, Laboratory Chemistry Specialist, at 266-1587. August 13, 2019 Beginning September 3, 2019, Tacrolimus (Prograf) testing (EPIC Test Code IMO477) will be performed using an electrochemiluminescence immunoassay methodology on Roche Cobas instrumentation. This is a change from the homogeneous particle-enhanced turbidimetric immunoassay method that is used currently. Because of this, there may be some variation from prior evaluations. Specimen requirements remain unchanged. Please refer questions about this method change to Dr. Qi Wang, Chemistry Technical Director, at 266-1641 or Ann Vick, Laboratory Chemistry Specialist, at 266-1587. June 12, 2019 Beginning June 19, 2019, monoclonal (M-spike) proteins identified on serum protein electrophoresis (EPIC Test Code LAB119) and serum immunofixation electrophoresis (EPIC Test Code LAB174) will be reported on their own result line instead of within an interpretive comment. This change is being made to allow for easier viewing and trending within EPIC. Please refer questions about this reporting change to Dr. Qi Wang, Chemistry Technical Director, at 266-1641 or Ann Vick, Laboratory Chemistry Specialist, at 266-1587. May 30, 2019 Troponin T, 5 th Generation Effective Tuesday, June 11, 2019, Parkview Health Laboratories will transition from the current Troponin T assay to a high-sensitive, Troponin T, Generation 5 assay (EPIC Test Code: LAB3111). Reporting will be in whole numbers utilizing units of ng/L. Gender specific reference ranges of (Female) 0-10 ng/L and (Male) 0-15 ng/L will be utilized. Values above 100 ng/L are considered to be critical and will be called. PST (light green) plasma specimen requirements remain the same. Please refer questions to Dr. Qi Wang, Chemistry Technical Director, at 266-1641 or Ann Vick, Laboratory Chemistry Specialist, at 266-1587. Algorithm for use with Troponin T, Generatio...